media – Page 9 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

A world first! AstraZeneca’s new hypertension drug approved for market launch.

On May 18, AstraZeneca announced that its baxdrostat (trade name: Baxfendy) has been approved in the United States as the first aldosterone synthase inhibitor (ASI) to be used in combination with other antihypertensive drugs to treat hypertension and lower blood pressure in adults with poorly controlled blood pressure. The product was submitted for market approval in China in February of this year. Source: AstraZeneca official website Baxdrostat is a first-in-class, highly selective aldosterone synthase inhibitor that lowers blood pressure by inhibiting aldosterone production. In February 2023, AstraZeneca acquired CinCor for $1.8 billion, gaining access to Baxdrostat . In December 2025, AstraZeneca submitted a marketing application for the product to the FDA and was granted priority review status, allowing it to be used as adjunctive therapy to other antihypertensive drugs in cases where these drugs fail to adequately lower blood pressure, for the treatment of adult patients with refractory hypertension (uncontrolled ...
- Source: drugdu
- 82
- May 19, 2026
Bio-Thera Solutions and Accord BioPharma jointly announced that the first golimumab biosimilars for Simponi®/Simponi Aria®, IMMGOLIS™ and IMMGOLIS INTRI™, have been approved by the U.S. FDA.

Bio-Thera Solutions, Ltd. (Stock Code: 688177 ) is a global biopharmaceutical company headquartered in Guangzhou, China, based on scientific innovation . Recently, the Company and Accord BioPharma (hereinafter referred to as ” Accord ” , a US subsidiary of Intas Pharmaceuticals focusing on the development of oncology, immunology, and central nervous system therapies) jointly announced that they have received notification from the US Food and Drug Administration ( FDA ) that two biosimilars developed by Bio-Thera, based on simponicity® golimumab ( BAT2506 ) – IMMGOLIS ™ ( golimumab-sldi ) (subcutaneous injection) and IMMGOLIS INTRI™ ( golimumab-sldi ) (intravenous infusion) – have received FDA approval for marketing in the United States. Among them, IMMGOLIS™ is approved for use in combination with methotrexate for the treatment of adult patients with moderate to severe active rheumatoid arthritis and for the treatment of adult patients with moderate to severe active ulcerative colitis; IMMGOLIS INTRI™ ...
- Source: drugdu
- 83
- May 19, 2026
CMEH SHANGHAI

Organiser：China Medical and Healthcare Industry Association, Chinese Medical Exchange Society Time：June 24 – June 26, 2026 Address：Shanghai World Expo Exhibition & Convention Center Exhibition hall：Shanghai World Expo Exhibition & Convention Center, No. 1099 Guozhan Road, Pudong New Area, Shanghai, China Product range: Medical Imaging: CT, DR, Medical X-ray Systems, Ultrasonic Diagnostic Instruments, Magnetic Resonance Equipment, Tumor Therapy Devices, Medical Films & Processing Systems, etc. Remote Mobile Smart Monitoring & Healthcare: Sleep Monitors, Remote ECG, Blood Pressure, Blood Oxygen & Body Temperature Monitoring, Cloud Blood Pressure Monitors, Bluetooth Blood Pressure & Glucose Monitoring, Wearable Medical Devices & Health Kiosks, etc. Diagnostic & Therapeutic Equipment: Endoscopy Systems, ENT (Ear, Nose & Throat) Treatment Instruments, Dynamic Analysis Instruments, Cryogenic/Low-Temperature Freezing Equipment, Dialysis Therapy Equipment, Emergency/First Aid Equipment, Surgical Instruments, Electrosurgical Units & Consumables, Laser Surgical Instruments, Ultrasonic Surgery, etc. Ward Nursing Equipment & Furniture: Beds, Carts, Tables, Cabinets, Racks, etc. Disinfection Products: Medical Air ...
- Source: drugdu
- 73
- May 19, 2026
This Time, VBP May Be Unavoidable

The 12th round of national Volume-Based Procurement (VBP) is underway, and Entresto (sacubitril/valsartan), familiar to many hypertension and heart failure patients, is once again being targeted after a narrow escape from last year’s procurement list. On May 15, Shanghai Sunshine Procurement Network published the “Announcement on Pre-filing of Drug Information for National Volume-Based Procurement.” This round includes 77 varieties for pre-filing, totaling 233 specifications — the largest scale in history. Among the varieties listed for pre-filing are several blockbuster drugs with annual sales of billions of RMB, including the immunosuppressant tacrolimus, the antiplatelet drug indobufen, and the antibiotic ceftazidime-avibactam. Most notably, sacubitril/valsartan sodium tablets — better known to hypertension patients as “Entresto” — has drawn the most attention. “Entresto” was developed by Novartis. It is the world’s first angiotensin receptor-neprilysin inhibitor (ARNI), with dual effects of lowering blood pressure and protecting the heart. It first entered the Chinese market in ...
- Source: drugdu
- 113
- May 18, 2026
The Pure Generic Drug Giant No Longer Exists

A new wave of upheaval and transformation has long since begun. Sun Pharmaceutical, India’s largest generic drugmaker, is acquiring Organon for $117.5 billion — the largest overseas acquisition in Indian pharmaceutical history — revealing the anxiety gripping the generic drug industry. With buyer consolidation in the U.S. market, persistent pricing pressure, and intensifying competition, even global generic giants are being swept along by industry trends, saying goodbye to the era of “easy money” in generics. As Sun Pharma Chairman Dilip Shanghvi stated, ‘This is a critical step in our strategic transformation. Organon’s specialty drug assets will help us escape the quagmire of generic price wars and build a sustainable growth engine.’ Before Sun Pharma, another generic giant, Teva Pharmaceutical, had already staged a turnaround through innovation-driven transformation, with its stock rising nearly 240% since 2024. These signals collectively point to a fact: the global generic drug industry is undergoing a ...
- Source: drugdu
- 81
- May 18, 2026
Ten departments, including the State Administration of Traditional Chinese Medicine, are cracking down on illegal and irregular practices related to traditional Chinese medicine.

Recently , ten departments, including the State Administration of Traditional Chinese Medicine, jointly convened a meeting to launch a special campaign to address illegal and irregular practices in traditional Chinese medicine (TCM) medical practice. This year-long campaign will severely crack down on illegal medical practices under the guise of TCM health preservation and disease treatment, false advertising and live-streaming sales using the name of TCM, and illegal use of medical insurance funds, among other illegal and irregular activities that harm the health rights of the public. In the short term, some small and medium-sized TCM institutions and health preservation companies that rely on false advertising, illegal medical practice, and illegal insurance fraud will face closure and penalties, and related concept stocks may experience a short-term correction, impacting market sentiment to some extent. However, in the long term, the special campaign will eliminate the “bad apples” in the industry, break the ...
- Source: drugdu
- 66
- May 18, 2026
Breaking News! Results of Two Studies on Smegglutinin Announced

The 33rd European Congress on Obesity (ECO 2026) was recently held in Istanbul, Türkiye. Novo Nordisk unveils two key data points: Higher doses of Wegovy injection (semaglutide 7.2 mg) resulted in nearly 28% weight loss in early responders; Wegovy oral tablets achieved a 21.6% weight loss and significantly improved physical activity in early responders. These two sets of data indicate that smegglutide has the best performance in its class in terms of comprehensive benefits such as weight loss, muscle health improvement, and improved mobility. 01 STEP UP subgroup analysis: Higher doses offer weight loss advantages The STEP UP trial was a 72-week, randomized, double-blind, parallel-group, placebo-controlled superiority trial designed to evaluate the efficacy and safety of semaglutide 7.2 mg as an adjunct to lifestyle interventions compared to semaglutide 2.4 mg and placebo. The trial enrolled over 1400 obese adults without type 2 diabetes. A recent subgroup analysis showed that, regardless ...
- Source: drugdu
- 71
- May 18, 2026
Synermore Biotech Receives Another International GMP Certification; Innovative Monoclonal Antibody Drug Cribi® Accelerates Global Expansion

On May 11, 2026, Synermore Biopharmaceutical (Suzhou) Co., Ltd. (“Synermore Biopharmaceutical”) announced that it had officially received the Good Manufacturing Practice (GMP) certificate issued by the Philippine Food and Drug Administration (FDA Philippines) . This is Synermore Biopharmaceutical’s second overseas GMP certification , following its acquisition of the Turkish GMP certificate at the end of 2025. This signifies that the production quality management system of its core product, Zamerovic-Mazoprevir Injection (trade name: Cribi®), continues to be recognized by overseas regulatory agencies, further accelerating its internationalization process. GMP certificate issued by the Philippine Food and Drug Administration (FDA Philippines) Krebi® is a Class I innovative drug independently developed by Synermore Biotechnology, used for passive immunization in adult individuals exposed to rabies virus. It is the first domestically produced anti-rabies cocktail monoclonal antibody that meets the recommendations of the World Health Organization (WHO) and was approved for marketing by the China National ...
- Source: drugdu
- 69
- May 18, 2026
AbbVie’s $3.9 billion drug has been approved for marketing in the country!

On May 15, the NMPA (National Medical Products Administration) announced on its website that AbbVie ‘s ectorituximab has been approved for marketing. The approved indication is for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) in combination with rituximab and lenalidomide. Previously, this marketing application had been included in the priority review pathway, accelerating its approval process. 01 A massive $3.9 billion investment to introduce next-generation innovative dual-antibody drugs. Icarutumab was originally developed by Genmab . In 2020, AbbVie and Genmab entered into a strategic collaboration worth $3.9 billion to jointly develop and commercialize three of Genmab ‘s next-generation bispecific antibody products, including Icarutumab . As an IgG1 type CD20×CD3 bispecific antibody, Icaretimab can simultaneously and precisely bind to CD3 on the surface of T cells and CD20 on the surface of B cells, effectively activating T cells and mediating their direct killing of lymphoma B ...
- Source: drugdu
- 83
- May 18, 2026
This is no small matter; CSPC Pharmaceutical Group’s new antidepressant has been submitted for its first generic version to market

Depression is a common mental illness characterized by high prevalence, high relapse rate, and high disease burden. While existing antidepressants are generally effective, unmet clinical needs remain regarding their speed of onset, remission rate, and patient adherence. Statistics show that the lifetime prevalence of depressive disorders among adults in China is as high as 6.8%, with 3.4% suffering from depression. Currently, the number of people suffering from depression is approaching 100 million, meaning one in every 14 people suffers from depression. On May 15, 2026, according to the latest information on the website of the Center for Drug Evaluation (CDE) of China, the marketing application for dextromethorphan-bupropion extended-release tablets submitted by CSPC Ouyi Pharmaceutical Co., Ltd. under Category 3 chemical drug registration was accepted. According to publicly available information , the drug’s indication is for the treatment of depression in adults . picture Publicly available information shows that dextromethorphan-bupropion extended-release ...
- Source: drugdu
- 56
- May 18, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.